Telix Pharmaceuticals Limited (TLX) P/E Ratio History
Deep ValueTrading at -480.2x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of October 3, 2026, Telix Pharmaceuticals Limited (TLX) trades at a price-to-earnings ratio of -480.2x, with a stock price of $10.55 and trailing twelve-month earnings per share of $0.23.
The current P/E is 749% below its 5-year average of 73.9x. Over the past five years, TLX's P/E has ranged from a low of 48.4x to a high of 97.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, TLX trades at a 2173% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, TLX trades at a notable discount to the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TLX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TLX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
TLX P/E vs Peers
Radiopharmaceuticals and Targeted Radiation peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $15B | 21.0 | 0.41Best | +58% | |
| $2B | 22.1 | - | +172% | |
| $7B | 29.3 | - | -22% | |
| $268B | 19.6 | 1.28 | +22% | |
| $125B | 17.7 | - | +178%Best | |
| $321B | 37.9 | 3.21 | +36% | |
| $29B | 14.1Lowest | - | +5% | |
| $106B | 32.8 | 2.21 | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
TLX Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $11.53 | $0.24 | 48.4x | -35% |
| FY2025 Q4 | Dec 31 2025 | $7.49 | $0.11 | 67.1x | -9% |
| FY2025 Q2 | Jun 30 2025 | $16.07 | $0.19 | 83.1x | +12% |
| FY2024 Q4 | - | $15.40 | $0.16 | 97.2x | +31% |
Average P/E for displayed period: 73.9x
TLX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TLX — Frequently Asked Questions
Quick answers to the most common questions about buying TLX stock.
What is TLX's P/E ratio?
Telix Pharmaceuticals Limited (TLX) trailing twelve-month P/E ratio is -480.2x, based on TTM diluted EPS of $0.23. The 5-year average P/E is 73.9x and the historical range spans 48.4x to 97.2x.
Is TLX stock overvalued or undervalued?
TLX trades at -480.2x P/E, below its 5-year average of 73.9x. At the 0th percentile of its historical range (48.4x–97.2x), the stock is priced at a discount to its own history.
Is TLX stock expensive?
No, TLX is not expensive on a historical basis. The current P/E of -480.2x is below the 5-year average of 73.9x and sits at the 0th percentile of its valuation range.
What is TLX's historical P/E range?
Over the past 5 years, TLX's P/E ratio has ranged from 48.4x to 97.2x, with a median of 83.1x and an average of 73.9x. The current P/E of -480.2x places the stock at the 0th percentile of this range. Full historical data spans 2024–2026.
How does TLX's P/E compare to the S&P 500?
TLX trades at -480.2x P/E versus the S&P 500 median of 24.5x. The 2060% discount to the market suggests lower growth expectations or perceived higher risk.
How does TLX's valuation compare to Healthcare peers?
Telix Pharmaceuticals Limited P/E of -480.2x compares to the Healthcare sector median of 23.2x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is TLX's PEG ratio?
TLX PEG ratio is N/A, based on a P/E of -480.2x and EPS growth of -122.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is TLX's earnings yield?
TLX earnings yield is N/A, the inverse of its -480.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.